NCT05642806View on ClinicalTrials.gov

Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment

PHASE4RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

June 30, 2025

Conditions
Chronic Rhinosinusitis With Nasal PolypsAsthmaChronic Rhinosinusitis Without Nasal Polyps
Interventions
BIOLOGICAL

Mepolizumab

Mepolizumab will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks

OTHER

Placebo

Placebo will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks

Trial Locations (1)

V6Z 1Y6

RECRUITING

St. Pual's Sinus Centre, Vancouver

All Listed Sponsors
lead

St. Paul's Sinus Centre

OTHER